Anaptysbio (ANAB) EBT (2016 - 2026)

Anaptysbio (ANAB) has 11 years of EBT data on file, last reported at -$52.8 million in Q1 2026.

• Quarterly EBT fell 34.51% year-over-year to -$52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.6 million (up 81.06% YoY) and the FY2025 annual result came in at -$13.1 million, up 91.0% from the prior year.
• EBT declined to -$52.8 million in Q1 2026, from $49.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $49.7 million in Q4 2025 to a low of -$62.6 million in Q1 2023.
• A 5-year average of -$33.0 million and a median of -$39.3 million in 2025 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT plunged 94.94% — and 2025, when it soared 328.06%.
• Tracing ANAB's EBT over 5 years: stood at -$22.7 million in 2022, then sank by 85.63% to -$42.2 million in 2023, then jumped by 48.33% to -$21.8 million in 2024, then surged by 328.06% to $49.7 million in 2025, then slumped by 206.34% to -$52.8 million in 2026.
• The last three EBT figures came in at -$52.8 million (Q1 2026), $49.7 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.